This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker (BRKR) to Support Biopharma Industries With New Buyout
by Zacks Equity Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.
Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays
by Zacks Equity Research
In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
by Zacks Equity Research
Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage
by Zacks Equity Research
Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
NextGen (NXGN) Introduces New Integrated Care EHR Solution
by Zacks Equity Research
NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.
Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.
Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.
Cardinal Health (CAH) to Extend Medical Distribution Presence
by Zacks Equity Research
Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.
Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay
by Zacks Equity Research
Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) robust international performance and strength in its GYN Surgical business.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Omnicell (OMCL) Progresses With Intelligent Infrastructure Tools
by Zacks Equity Research
Omnicell's (OMCL) IVX Station robotic compounding technology apparently supports three times the throughput speed of the current IV robotic technology.
LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.
Zacks Industry Outlook Highlights McKesson, West Pharmaceutical Services and Cardinal Health
by Zacks Equity Research
McKesson, West Pharmaceutical Services and Cardinal Health have been highlighted in this Industry Outlook article.
Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.